DE68925660D1 - Peptidfragmente von HIV - Google Patents

Peptidfragmente von HIV

Info

Publication number
DE68925660D1
DE68925660D1 DE68925660T DE68925660T DE68925660D1 DE 68925660 D1 DE68925660 D1 DE 68925660D1 DE 68925660 T DE68925660 T DE 68925660T DE 68925660 T DE68925660 T DE 68925660T DE 68925660 D1 DE68925660 D1 DE 68925660D1
Authority
DE
Germany
Prior art keywords
isoleucine
arginine
lysine
eucine
valine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE68925660T
Other languages
English (en)
Other versions
DE68925660T2 (de
Inventor
Andrew James Mcmichael
Douglas Fraser Nixon
Alain Robert Michael Townsend
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United Biomedical Inc
Original Assignee
United Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27263941&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE68925660(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB888813746A external-priority patent/GB8813746D0/en
Priority claimed from GB888815956A external-priority patent/GB8815956D0/en
Priority claimed from GB888826445A external-priority patent/GB8826445D0/en
Application filed by United Biomedical Inc filed Critical United Biomedical Inc
Application granted granted Critical
Publication of DE68925660D1 publication Critical patent/DE68925660D1/de
Publication of DE68925660T2 publication Critical patent/DE68925660T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE68925660T 1988-06-10 1989-06-02 Peptidfragmente von HIV Revoked DE68925660T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB888813746A GB8813746D0 (en) 1988-06-10 1988-06-10 Peptide fragments of hiv
GB888815956A GB8815956D0 (en) 1988-07-05 1988-07-05 Peptide fragments of hiv
GB888826445A GB8826445D0 (en) 1988-11-11 1988-11-11 Peptide fragments of hiv

Publications (2)

Publication Number Publication Date
DE68925660D1 true DE68925660D1 (de) 1996-03-28
DE68925660T2 DE68925660T2 (de) 1996-09-26

Family

ID=27263941

Family Applications (2)

Application Number Title Priority Date Filing Date
DE68925660T Revoked DE68925660T2 (de) 1988-06-10 1989-06-02 Peptidfragmente von HIV
DE198989305604T Pending DE346022T1 (de) 1988-06-10 1989-06-02 Peptidfragmente von hiv.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE198989305604T Pending DE346022T1 (de) 1988-06-10 1989-06-02 Peptidfragmente von hiv.

Country Status (7)

Country Link
US (2) US5459238A (de)
EP (1) EP0346022B1 (de)
JP (1) JPH0236198A (de)
AT (1) ATE134195T1 (de)
DE (2) DE68925660T2 (de)
GB (1) GB2220939B (de)
HK (1) HK141594A (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128319A (en) * 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
GB2220939B (en) * 1988-06-10 1992-02-26 Medical Res Council Peptide fragments of hiv and their use in vaccines and diagnosis
CA2072351A1 (en) * 1990-01-05 1991-07-06 Andrew J. Mcmichael Hiv-1 core protein fragments
US5336758A (en) * 1990-03-09 1994-08-09 The United States Of America As Represented By The Department Of Health And Human Services Peptides stimulating cytotoxic T cells immune to HIV RT
GB9014294D0 (en) * 1990-06-27 1990-08-15 Medical Res Council Assay for cytotoxic t cells
WO1992000098A1 (en) * 1990-06-29 1992-01-09 Daniel Zagury Methods of inducing immune response to aids virus
GB9125024D0 (en) * 1991-11-25 1992-01-22 Kirby Julian Rheumatoid arthritus treatment
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US6682731B1 (en) * 1994-03-24 2004-01-27 Ludwig Institute For Cancer Research Isolated peptides derived from mage tumor rejection antigen precursors which complex with HLA-A2 molecules
RS50101B (sr) * 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju
JP3693491B2 (ja) * 1997-07-11 2005-09-07 株式会社カネカ 改良された再生コラーゲン繊維及びその製造方法
DE19814701A1 (de) * 1998-04-01 1999-10-07 Rudolf Wank Verwendung von stimulierten mononukleären Zellen des peripheren Blutes zur Behandlung von mit dem Gehirn assoziierten Erkrankungen, Störungen und Schädigungen
AU1075001A (en) * 1999-10-05 2001-05-10 Epimmune, Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
DK1240186T3 (da) * 1999-12-23 2010-05-31 Medical Res Council Forbedringer i eller relateret til immunrespons mod HIV
DE10120505A1 (de) 2001-04-26 2002-11-07 Rudolf Wank Verwendung von stimulierten mononukleären Zellen des peripheren Blutes zur Behandlung von Krebserkrankungen
EP2745845A1 (de) 2012-12-19 2014-06-25 Centre Hospitalier Universitaire de Bordeaux Verfahren zur Vorbeugung oder Behandlung einer HIV-Infektion

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554088A (en) * 1983-05-12 1985-11-19 Advanced Magnetics Inc. Magnetic particles for use in separations
DE122005000039I1 (de) * 1984-10-18 2006-02-23 Pasteur Institut DNS-Fragmente des GAG-Gens von LAV
FR2582103B1 (fr) * 1985-03-19 1989-05-05 Canavaggio Michel Procede de determination d'une substance biologique dans un echantillon
US4629783A (en) * 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
ATE116006T1 (de) * 1985-04-29 1995-01-15 Genetic Systems Corp Synthetische antigene zum nachweis von aids.
ES2054616T3 (es) * 1985-12-17 1994-08-16 Akzo Nv Reactivo inmunoquimico.
EP0230222A1 (de) * 1986-01-06 1987-07-29 F. Hoffmann-La Roche Ag Expression des HTLV-III Gag-Gens
US4772547A (en) * 1986-02-03 1988-09-20 Hoffmann-La Roche Inc. HTLV-III envelope peptides
US4808536A (en) * 1986-02-27 1989-02-28 Centocor, Inc. Immunochemical method for detection of antibody against HTLV-III core protein based upon recombinant HTLV-III gag gene encoded protein
ZA873215B (en) * 1986-05-19 1987-10-28 Viral Technologies Inc. Htlv-iii/lav virus related peptides,antibodies to the peptides,vaccines,passive and active immunization against aids virus and diagnostic test for the serological detection of aids virus
GB8629116D0 (en) * 1986-12-05 1987-01-14 Hoffmann La Roche Env/gag polypeptides
ES2104556T3 (es) * 1987-01-16 1997-10-16 Pasteur Institut Peptidos que tienen propiedades inmunologicas de hiv-2.
NO881151L (no) * 1987-03-27 1988-09-28 Syntello Ab Syntetisk hiv-1-antigen.
US5100777A (en) * 1987-04-27 1992-03-31 Tanox Biosystems, Inc. Antibody matrix device and method for evaluating immune status
CA1339363C (en) * 1987-05-01 1997-08-26 Alan Ray Flesher Monoclonal antibodies to specific antigenic regions of the human immunodeficiency virus and methods for use
WO1989002277A2 (en) * 1987-08-28 1989-03-23 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
EP0330359A3 (de) * 1988-02-25 1991-06-05 Bio-Rad Laboratories, Inc. Zusammensetzung, verwendbar zur Diagnose und Behandlung von HIV-I-Infektion
GB2220939B (en) * 1988-06-10 1992-02-26 Medical Res Council Peptide fragments of hiv and their use in vaccines and diagnosis
EP0356007A3 (de) * 1988-07-22 1991-07-03 Medical Research Council Antigenische Determinanten
GB8918200D0 (en) * 1989-08-09 1989-09-20 Medical Res Council The peptide fragments of hiv
CA2072351A1 (en) * 1990-01-05 1991-07-06 Andrew J. Mcmichael Hiv-1 core protein fragments

Also Published As

Publication number Publication date
GB2220939A (en) 1990-01-24
JPH0236198A (ja) 1990-02-06
GB2220939B (en) 1992-02-26
EP0346022A1 (de) 1989-12-13
DE68925660T2 (de) 1996-09-26
EP0346022B1 (de) 1996-02-14
US5459238A (en) 1995-10-17
DE346022T1 (de) 1990-05-23
US5683701A (en) 1997-11-04
HK141594A (en) 1994-12-23
ATE134195T1 (de) 1996-02-15
GB8912651D0 (en) 1989-07-19

Similar Documents

Publication Publication Date Title
GB2255093A (en) Hiv-1 core protein fragments
DE68925660D1 (de) Peptidfragmente von HIV
DE3588254D1 (de) Gag-Antigen und dessen Verwendung zum Nachweis von LAV-Infektion, sowie in immunogenen Zusammensetzungen
DE68928130T2 (de) Synthetische vom HIV-GP120-env-Protein abgeleitete Peptide und ihre Anwendung
WO1989002277A3 (en) Prophylaxis and therapy of acquired immunodeficiency syndrome
DE69007571D1 (de) Peptidfragmente von HIV.
WO1993014206A3 (en) Synthetic peptides for a rubella vaccine
AU4712993A (en) New peptides, antibodies raised against peptides and means for blocking said antibodies, application as medicaments, pharmaceutical compositions and utilization methods
ES2071038T3 (es) Peptidos asociados al hiv.
DE69433057D1 (de) Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation